Novo Nordisk's Ozempic Drug Faces Declining Sales -- Market Talk

Dow Jones

03-24

1019 GMT - Novo Nordisk's diabetes treatment Ozempic faces falling sales amid U.S. share loss and price declines, Intron Health analysts write. "New analysis makes us more concerned about Ozempic 2025 sales, than Wegovy. We are now 8% below the mid-point of [group] 2025 guidance on sales and EBIT." Intron Helath is 40% below 2030 consensus Ozempic sales, which could translate to a 16% cut to 2030 consensus group EBIT. The analysts suggest a profit warning is possible at or before first quarter results on May 7. However, results from a trial testing semaglutide as a treatment for Alzheimer's due this year "could be game changing." Intron Helath downgrades Novo to sell from buy and lowers its target price to 460 Danish kroner from 880 kroner. Shares fall 2.6% to 515.00 kroner. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

March 24, 2025 06:19 ET (10:19 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2521717557"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2521717557\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2521717557?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-24 18:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2521717557","market":"hk","top_or_hot":-1,"title":"Novo Nordisk's Ozempic Drug Faces Declining Sales -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1019 GMT - Novo Nordisk's diabetes treatment Ozempic faces falling sales amid U.S. share loss and price declines, Intron Health analysts write. \"New analysis makes us more concerned about Ozempic 2025 sales, than Wegovy. We are now 8% below the mid-point of [group] 2025 guidance on sales and EBIT.\" Intron Helath is 40% below 2030 consensus Ozempic sales, which could translate to a 16% cut to 2030 consensus group EBIT. The analysts suggest a profit warning is possible at or before first quarter results on May 7. However, results from a trial testing semaglutide as a treatment for Alzheimer's due this year \"could be game changing.\" Intron Helath downgrades Novo to sell from buy and lowers its target price to 460 Danish kroner from 880 kroner. Shares fall 2.6% to 515.00 kroner. (dominic.chopping@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 24, 2025 06:19 ET (10:19 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk's Ozempic Drug Faces Declining Sales -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk's Ozempic Drug Faces Declining Sales -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-03-24 18:19</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1019 GMT - Novo Nordisk's diabetes treatment Ozempic faces falling sales amid U.S. share loss and price declines, Intron Health analysts write. \"New analysis makes us more concerned about Ozempic 2025 sales, than Wegovy. We are now 8% below the mid-point of [group] 2025 guidance on sales and EBIT.\" Intron Helath is 40% below 2030 consensus Ozempic sales, which could translate to a 16% cut to 2030 consensus group EBIT. The analysts suggest a profit warning is possible at or before first quarter results on May 7. However, results from a trial testing semaglutide as a treatment for Alzheimer's due this year \"could be game changing.\" Intron Helath downgrades Novo to sell from buy and lowers its target price to 460 Danish kroner from 880 kroner. Shares fall 2.6% to 515.00 kroner. (dominic.chopping@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 24, 2025 06:19 ET (10:19 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"諾和諾德","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2521717557","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2521717557","pubTimestamp":1742811540,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1019 GMT - Novo Nordisk's diabetes treatment Ozempic faces falling sales amid U.S. share loss and price declines, Intron Health analysts write. \"New analysis makes us more concerned about Ozempic 2025 sales, than Wegovy. We are now 8% below the mid-point of [group] 2025 guidance on sales and EBIT.\" Intron Helath is 40% below 2030 consensus Ozempic sales, which could translate to a 16% cut to 2030 consensus group EBIT. The analysts suggest a profit warning is possible at or before first quarter results on May 7. However, results from a trial testing semaglutide as a treatment for Alzheimer's due this year \"could be game changing.\" Intron Helath downgrades Novo to sell from buy and lowers its target price to 460 Danish kroner from 880 kroner. Shares fall 2.6% to 515.00 kroner. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"诺和诺德的Ozempic药物面临销售额下降——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"1019 GMT - Novo Nordisk's diabetes treatment Ozempic faces falling sales amid U.S. share loss and price declines, Intron Health analysts write. \"New analysis makes us more concerned about Ozempic 2025 sales, than Wegovy. We are now 8% below the mid-point of [group] 2025 guidance on sales and EBIT.\" Intron Helath is 40% below 2030 consensus Ozempic sales, which could translate to a 16% cut to 2030 consensus group EBIT. The analysts suggest a profit warning is possible at or before first quarter results on May 7. However, results from a trial testing semaglutide as a treatment for Alzheimer's due this year \"could be game changing.\" Intron Helath downgrades Novo to sell from buy and lowers its target price to 460 Danish kroner from 880 kroner. Shares fall 2.6% to 515.00 kroner. (dominic.chopping@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 24, 2025 06:19 ET (10:19 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}